Alport Syndrome Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight | Eloxx Pharmaceuticals, River 3 Renal Corp, Chinook Therapeutic, Travere Therapeutics, Reata Pharmaceuticals

DelveInsight's "Alport Syndrome Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of Alport Syndrome , historical and forecasted epidemiology as well as the Alport Syndrome market trends in the US, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Discover which therapies are expected to grab the Alport Syndrome Market Share @ Alport Syndrome Market Outlook- https://www.delveinsight.com/sample-request/alport-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Alport Syndrome Market Report
• The total number of prevalent cases of Alport syndrome in the 7MM were ~159,000 in 2023.
• Alport syndrome is more prevalent in adult population with ~86% contribution in the 7MM, while pediatric population accounted for ~14% cases.
• The X-linked alport syndrome (XLAS) is most prevalent subtype of Alport syndrome with around 11,500 cases in 2023 in the US while autosomal dominant alport syndrome (ADAS) being the least prevalent subtype of alport syndrome.
• In EU4 region, the total prevalent cases were the highest in Germany, with nearly 17,000 cases in 2023, while Spain had the least number of cases in 2023.
• Alport syndrome affects both men and women in the United States with minimal disparity, although men are slightly more impacted than women.
• The leading Alport Syndrome Companies such as Eloxx Pharmaceuticals, River 3 Renal Corp, Chinook Therapeutic, Travere Therapeutics, Reata Pharmaceuticals, and others.
• Promising Alport Syndrome Pipeline Therapies such as ELX-02, Atrasentan, Finerenone, Setanaxib, BAY3401016, and others.

Stay ahead in the Gene Therapy for Alport Syndrome with DelveInsight's Strategic Report @ Alport Syndrome Market Outlook- https://www.delveinsight.com/sample-request/alport-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Alport Syndrome Epidemiology Segmentation in the 7MM
The epidemiology section of Alport Syndrome offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

Download the report to understand which factors are driving Alport Syndrome Epidemiology trends @ Alport Syndrome Prevalence- https://www.delveinsight.com/sample-request/alport-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Emerging Alport syndrome Drugs
• ELX-02: Eloxx Pharmaceuticals
Eloxx's lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore the production of full-length functional proteins. It is a synthetic aminoglycoside administered through the subcutaneous route and inhalational route. It optimizes ribosomal read-through of premature termination codons (PTC), through which full-length functional proteins can be produced. It acts by targeting CFTR. Preclinical studies support ELX-02 activity in nonsense mutation genetic kidney diseases.

• Atrasentan: Chinook Therapeutics/Novartis
Atrasentan is a potent and selective endothelin A (ETA) receptor antagonist that has the potential to provide benefit in multiple chronic kidney diseases such as IgA nephropathy (IgAN) and other proteinuric glomerular diseases by reducing proteinuria and having direct anti-inflammatory and anti-fibrotic effects to preserve kidney function. The company in-licensed atrasentan from AbbVie in December 2019, which previously developed atrasentan for diabetic kidney disease (DKD).

Alport syndrome Drugs Market Insights
There is a growing focus on sodium-glucose cotransporter-2 (SGLT2) inhibitors as potential agents to decelerate the progression of chronic kidney disease. Due to their existing approval for hypoglycemic effects, there is considerable interest in the off-label use of these agents for individuals with Alport syndrome. ACE inhibitors and ARBs form the current mainstay treatment for CKD in Alport syndrome. However, in the past few years, interest in developing new treatments has increased significantly. The late-stage pipeline of Alport syndrome is not that strong with few therapies only, including a small molecule gene therapy ELX-02 (Eloxx Pharmaceuticals) for patients with a nonsense mutation only; other therapies are Atrasentan (Novartis) and Finerenone (Bayer). Setanaxib by Calliditas Therapeutics completed its preclinical trial and is now planning for Phase II, while Bayer has already started a Phase I trial of Semaphorin-3A in healthy subjects.

To learn more about Alport Syndrome treatment guidelines, visit @ Alport Syndrome Treatment Market Landscape- https://www.delveinsight.com/sample-request/alport-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Alport Syndrome Companies
Eloxx Pharmaceuticals, River 3 Renal Corp, Chinook Therapeutic, Travere Therapeutics, Reata Pharmaceuticals, and others.

Alport Syndrome Market Outlook
Alport syndrome comes with many challenges and lacks real-world treatment prescription studies, but some researchers have tried their best to make the utilization of drugs a bit clear. As there is no approved therapy for this condition, the treatment is often off-label. National Kidney Foundation and the Alport Syndrome Foundation published a document and discussed this condition. It was found that approximately 52% of the patients receive ACE/ARB, and various other medications such as a statin, Allopurinol, antidepressants, and others are also prescribed to manage the symptoms, and many patients also use drug-device combinations.

Learn more about the FDA-approved drugs for Alport Syndrome @ Gene Therapy for Alport Syndrome- https://www.delveinsight.com/sample-request/alport-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Alport Syndrome Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Alport Syndrome Companies- Eloxx Pharmaceuticals, River 3 Renal Corp, Chinook Therapeutic, Travere Therapeutics, Reata Pharmaceuticals, and others.
• Alport Syndrome Pipeline Therapies- ELX-02, Atrasentan, Finerenone, Setanaxib, BAY3401016, and others.
• Alport Syndrome Market Dynamics: Alport Syndrome Market Drivers and Barriers
• Alport Syndrome Market Access and Reimbursement, Unmet Needs and Future Perspectives, Alport Syndrome Clinical Trials

Discover more about Alport Syndrome Drugs in development @ Alport Syndrome Clinical Trials Assessment- https://www.delveinsight.com/sample-request/alport-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Alport Syndrome Market Report Introduction
3. Executive Summary of Alport Syndrome
4. Epidemiology and Market Forecast Methodology
5. Key Events
6. Alport Syndrome Market Overview at a Glance
7. Disease Background and Overview
8. Treatment of Alport Syndrome
9. Diagnostic and Treatment Guidelines
10. Alport Syndrome Epidemiology and Patient Population
11. Alport Syndrome Patient Journey
12. Alport Syndrome Emerging Therapies
13. Alport Syndrome: 7MM Market Analysis
14. Alport Syndrome Unmet Needs
15. Alport Syndrome SWOT Analysis
16. Alport Syndrome KOL Views
17. Alport Syndrome Market Access and Reimbursement
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

List of Top Selling Market Research Reports in 2025

ADHD Market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
NK Cell Therapy Market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
Indwelling catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
Lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market
Vital sign monitors devices market- https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market
Cardiac implantable electronic devices market- https://www.delveinsight.com/report-store/cardiac-implantable-electronic-devices-cieds-market
HIP replacement devices market- https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
Positive airway pressure device market- https://www.delveinsight.com/report-store/positive-airway-pressure-device-market
Surgical robotic system market- https://www.delveinsight.com/report-store/surgical-robotic-system-market
Stem cell market- https://www.delveinsight.com/report-store/stem-cell-market
Thrombectomy devices market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
Thyroid cancer market- https://www.delveinsight.com/report-store/thyroid-cancer-market
ly3454738 drug insight- https://www.delveinsight.com/report-store/moderate-to-severe-atopic-dermatitis-pipeline-insight
Surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Healthcare competitive benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
Antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Medical marijuana market- https://www.delveinsight.com/report-store/medical-marijuana-market-insight
Bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us
Yash Bhardwaj
info@delveinsight.com
https://www.delveinsight.com/

This release was published on openPR.